Treatment
Cell clinical trials
We’re tracking 5,682 recruiting studies that include Cell, each written for real people, not researchers, below.
Recruiting studies
- NCT07016737Enrolling by invitationPhase 3
Chemotherapy and radiation for returning esophageal cancer
This trial tests if adding radiation before and after standard chemotherapy can help people whose esophageal cancer has come back after initial treatment. It aims to improve control of the cancer while keeping side effects manageable.
Nanjing, JiangsuAges 18 years+ - NCT06931613Enrolling by invitationPhase 2
STEM CELL TRANSPLANT FOR HODGKIN LYMPHOMA AFTER NIVOLUMAB
This trial tests a stem cell transplant using your own cells for children and teens with Hodgkin lymphoma that has come back or not gotten better after multiple treatments. It involves using a medicine called nivolumab before the transplant to help your body fight the cancer.
MoscowAges 2–18 - NCT06902792Enrolling by invitationPhase 1
Adebrelimab and trametinib for children with hard-to-treat LCH
This trial tests a combination of two drugs for children and teens with Langerhans cell histiocytosis (LCH) that has not responded to standard treatments or has come back after treatment. The goal is to see if the drugs can shrink lesions and improve symptoms.
Wenzhou, ZhejiangAges Up to 18 years - NCT06888973Enrolling by invitationPhase 1/Phase 2
Stem cell infusion for autoimmune diseases
This clinical trial is testing if infusions of special stem cells (called mesenchymal stem cells) can help people with certain autoimmune diseases where standard treatments have not worked well enough. It is an early-phase study in Pakistan for adults (and some children for one condition) with rheumatoid arthritis, lupus, systemic sclerosis, ankylosing spondylitis, or dermatomyositis/polymyositis.
RawalpindiAges 18–50 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06876675Enrolling by invitation
Lorlatinib and high cholesterol in ALK+ lung cancer
This study looks at how the drug Lorlatinib affects cholesterol levels in people with ALK-positive non-small cell lung cancer. It aims to understand and manage these side effects better.
BeijingAges 18–80 - NCT06827782Enrolling by invitationPhase 1
Cord blood CAR-NK cells for relapsed CNS lymphoma
This trial tests a new treatment using specially engineered immune cells from cord blood to target and kill cancer cells in the brain or spine. It is for people whose central nervous system lymphoma has not responded to or has returned after previous treatments.
Hangzhou, ZhejiangAges 18–75 - NCT06810895Enrolling by invitation
Immunotherapy plus chemo for recurrent cervical cancer
This trial tests a new immunotherapy drug called cadonilimab (AK104) combined with standard chemotherapy for women whose small cell neuroendocrine cervical cancer has returned or spread. The goal is to see if this combination helps shrink tumors or slow the cancer better than chemotherapy alone.
WuhanAges 18–75 - NCT06790498Enrolling by invitation
Long-term follow-up after renal cell therapy for kidney disease
This study follows people who previously received an experimental treatment called REACT for chronic kidney disease in earlier clinical trials. Its goal is to monitor their health over time.
Meridian, IdahoAges 30–80 - NCT06773156Enrolling by invitationPhase 2
Adebrelimab plus apatinib after chemoradiation for limited-stage SCLC
This trial tests whether adding two drugs (adebrelimab and apatinib) after standard chemoradiation can help prevent cancer from coming back in people with limited-stage small cell lung cancer. It is for patients whose cancer did not grow after chemoradiation.
Nanchang, JiangxiAges 18–75 - NCT06764329Enrolling by invitationPhase 1/Phase 2
Stem cell therapy for male hair loss
This trial tests if injecting donor stem cells into the scalp can help regrow hair in men with male pattern baldness. It may offer a new option for those who haven't found other treatments effective.
RawalpindiAges 20–59 - NCT06759857Enrolling by invitationPhase 3
New drug vs. afatinib for EGFR-mutant lung cancer
This trial compares a new drug (FHND9041) to a standard targeted therapy (afatinib) for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if the new drug works better or has fewer side effects.
BeijingAges 1.5 years+ - NCT06730685Enrolling by invitation
Sarcopenia and cachexia in lung cancer patients
This study looks at muscle loss (sarcopenia) and weight loss (cachexia) in people with lung cancer. Researchers want to understand these conditions better to improve care.
Næstved, Region SjællandAges 18 years+ - NCT06690216Enrolling by invitationPhase 1/Phase 2
PET scan study for PD-L1 in certain cancers
This trial tests a new PET imaging agent, [18F]AlF-NOTA-PCP2, to detect PD-L1 protein in tumors. It may help guide treatment decisions for people with glioblastoma, head and neck, lung, or esophageal cancer.
Jinan, ShandongAges 18 years+ - NCT06665490Enrolling by invitation
Skin care wash study for mycosis fungoides
This study tests whether a special skin care body wash can improve skin lesions in people with mycosis fungoides, a type of skin lymphoma. Researchers will look at skin bacteria before and after using the wash.
Chicago, IllinoisAges 18–89 - NCT06529042Enrolling by invitation
Sickle Cell Risk in Pregnancy Tool Study
This study is developing a risk assessment tool to help predict complications in pregnant women with sickle cell disease. It reviews medical records from women who have received prenatal care and given birth at participating hospitals.
Baltimore, MarylandAges 16–60 - NCT06505135Enrolling by invitationPhase 1
Stem cells for rotator cuff tear repair
This study tests whether injecting your own stem cells (taken from belly fat) during rotator cuff repair helps the tendon heal better and reduces pain. It's for people with a recent, repairable tear who are otherwise healthy.
Sønderborg, DanmarkAges 40–69 - NCT06419179Enrolling by invitationPhase 2
Maintenance therapy for HRD-positive small-cell lung cancer
This trial tests whether a combination of two medications, durvalumab and olaparib, can help keep your extensive-stage small-cell lung cancer from coming back after standard first-line treatment. It is for people whose tumors have a specific genetic feature called HRD.
Cologne, North Rhine-WestphaliaAges 18–120 - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT06303583Enrolling by invitationPhase 1/Phase 2
Chemo-radiation followed by immunotherapy for esophageal cancer
This trial tests if giving chemotherapy and radiation before surgery, followed by immunotherapy, can improve outcomes for people with a specific type of esophageal cancer that can be surgically removed.
Hangzhou, ZhejiangAges 18–75 - NCT06253507Enrolling by invitationPhase 1/Phase 2
Gene therapy for p47 chronic granulomatous disease
This trial tests a new gene therapy for people with a specific type of chronic granulomatous disease (p47 CGD). The treatment uses your own blood stem cells, which are modified in a lab to help your body fight infections better. It is for people who do not have a matched stem cell donor and have had serious infections.
Bethesda, MarylandAges 3–65 - NCT06163508Enrolling by invitation
Long-term follow-up for Q-Cells recipients
This study is for people who have already received Q-Cells treatment. It does not test new treatments; instead, it checks on your health over a long time to see how you are doing.
Dallas, TexasAges Any age - NCT06048926Enrolling by invitation
Carrelizumab with chemoradiation for advanced esophageal cancer
This trial tests combining the immunotherapy drug carrelizumab with standard chemotherapy and radiation for people with advanced esophageal cancer that cannot be surgically removed. It aims to see if this combination can help shrink or control the tumor.
NanjingAges 18–75 - NCT05509855Enrolling by invitation
Long-term safety follow-up for WU-CART-007 treatment
This study checks how safe WU-CART-007 is over time after you received it. It mainly helps doctors understand long-term side effects and outcomes.
Duarte, CaliforniaAges 12 years+
Common questions
- Are there clinical trials studying Cell?
- Yes. Clin2 currently lists 5,682 recruiting studies that include Cell, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Cell trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Cell an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Cell or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.